Literature DB >> 20508949

Comparative study of stromal metalloproteases expression in patients with benign hyperplasia and prostate cancer.

Safwan Escaff1, Jesús M Fernández, Luis O González, Aurelio Suárez, Salomé González-Reyes, José M González, Francisco J Vizoso.   

Abstract

PURPOSE: The aim of the present work was to perform a comparative study of stromal cell expressions of MMPs and TIMPs between benign and malignant prostate tissues.
METHODS: An immunohistochemical study was performed using specific antibodies against metalloproteases (MMPs) -1, -2, -7, 9, 11, 13, 14 and their tissue inhibitors (TIMPs) -1, 2 and 3, on prostate specimens from 133 patients with clinical localized prostate carcinoma and from 50 patients with BPH.
RESULTS: Our results showed higher percentages of expressions of MMPs and TIMPs by fibroblasts or by mononuclear inflammatory cells (MICs) in prostate carcinomas compared to these cells in BPH. The detection of MMP-2 expression by stromal fibroblasts and/or MMP-2, 9 and TIMP-3 expression by stromal MICs was associated with a 100% of specificity for diagnoses of prostate cancer. We found that the combination of MMP-2 expression by fibroblasts and/or MMP-9 by MICs and/or TIMP-2 by MICs yielded a sensitivity of 47.4%.
CONCLUSIONS: Despite of a limited sensitivity (50%), the combination of MMP-TIMPs expression in stromal cells (MMP-2 by fibroblasts and TIMPs by MICs) in our study provided a specificity of 100% for prostate cancer diagnosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20508949     DOI: 10.1007/s00432-010-0906-8

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  22 in total

1.  Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.

Authors:  T A Stamey; N Yang; A R Hay; J E McNeal; F S Freiha; E Redwine
Journal:  N Engl J Med       Date:  1987-10-08       Impact factor: 91.245

2.  Demonstration in vivo that stromelysin-3 functions through its proteolytic activity.

Authors:  A Noël; A Boulay; F Kebers; R Kannan; A Hajitou; C M Calberg-Bacq; P Basset; M C Rio; J M Foidart
Journal:  Oncogene       Date:  2000-03-16       Impact factor: 9.867

3.  Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5 ml) in whole-mount prostatectomy specimens.

Authors:  Liang Cheng; Timothy D Jones; Chong-Xian Pan; Ayana Barbarin; John N Eble; Michael O Koch
Journal:  Mod Pathol       Date:  2005-08       Impact factor: 7.842

4.  Control of matrix metalloproteinase activity in cancer.

Authors:  J L Jones; R A Walker
Journal:  J Pathol       Date:  1997-12       Impact factor: 7.996

Review 5.  Tissue inhibitor of metalloproteinases-1 in breast cancer.

Authors:  S Ø Würtz; A-S Schrohl; N Møller Sørensen; U Lademann; I J Christensen; H Mouridsen; N Brünner
Journal:  Endocr Relat Cancer       Date:  2005-06       Impact factor: 5.678

Review 6.  Complex roles of tissue inhibitors of metalloproteinases in cancer.

Authors:  Yangfu Jiang; Itzhak D Goldberg; Y Eric Shi
Journal:  Oncogene       Date:  2002-03-28       Impact factor: 9.867

7.  Matrix metalloproteinases: biologic activity and clinical implications.

Authors:  A R Nelson; B Fingleton; M L Rothenberg; L M Matrisian
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

8.  Matrilysin [MMP-7] expression selects for cells with reduced sensitivity to apoptosis.

Authors:  B Fingleton; T Vargo-Gogola; H C Crawford; L M Matrisian
Journal:  Neoplasia       Date:  2001 Nov-Dec       Impact factor: 5.715

9.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.

Authors:  J I Epstein; P C Walsh; M Carmichael; C B Brendler
Journal:  JAMA       Date:  1994-02-02       Impact factor: 56.272

10.  Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray.

Authors:  Robin L Parker; David G Huntsman; David W Lesack; James B Cupples; Dennis R Grant; Majid Akbari; C Blake Gilks
Journal:  Am J Clin Pathol       Date:  2002-05       Impact factor: 2.493

View more
  4 in total

1.  Association between MMP-2 expression and prostate cancer: A meta-analysis.

Authors:  Tiancheng Xie; Binbin Dong; Yangye Yan; Guanghui Hu; Yunfei Xu
Journal:  Biomed Rep       Date:  2015-12-08

2.  Matrix metalloproteinase 2 overexpression and prognosis in colorectal cancer: a meta-analysis.

Authors:  Mumu Shi; Bo Yu; Hongguo Gao; Jingwen Mu; Changwei Ji
Journal:  Mol Biol Rep       Date:  2012-11-27       Impact factor: 2.316

Review 3.  The Role of the Metzincin Superfamily in Prostate Cancer Progression: A Systematic-Like Review.

Authors:  Marley J Binder; Alister C Ward
Journal:  Int J Mol Sci       Date:  2021-03-30       Impact factor: 5.923

4.  Small antibody fusion proteins with complementarity-determining regions and lidamycin for tumor targeting therapy.

Authors:  Gen-Shen Zhong; Min-Na Wu; Xiao-Fang Guo; Zhi-Shan Xu; Sheng-Hua Zhang; Yong-Su Zhen
Journal:  Oncol Lett       Date:  2013-01-18       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.